Last updated: September 8, 2026
Sodium fluoride F-18 is a mature PET radiopharmaceutical used to image areas of increased osteoblastic activity, primarily in the evaluation of skeletal disease. Its commercial outlook is driven by PET scanner capacity, local radiopharmacy distribution, oncology imaging demand, and reimbursement rather than patent exclusivity. The product has limited direct revenue transparency because manufacturers generally report nuclear-medicine revenue by portfolio instead of by radiopharmaceutical.
What is the current market position of sodium fluoride F-18?
Sodium fluoride F-18, also written as NaF F-18 or sodium fluoride F-18 injection, is an injectable PET diagnostic agent. It localizes in bone through exchange with hydroxyl groups in hydroxyapatite and produces high skeletal uptake on PET imaging.
The FDA approved sodium fluoride F-18 injection for PET imaging of bone to define areas of altered osteogenic activity in patients with suspected or known skeletal abnormalities [1]. Its principal commercial applications include:
| Application |
Commercial relevance |
| Detection of osseous metastases |
Largest potential use in oncology |
| Evaluation of suspicious bone lesions |
Supports diagnostic workups |
| Assessment of osteoblastic activity |
Useful in selected orthopedic and metabolic conditions |
| Treatment-response evaluation |
Used selectively, depending on clinical protocol |
| Research and clinical trials |
Smaller, institution-dependent segment |
NaF PET provides higher spatial resolution and faster acquisition than conventional technetium-99m bone scintigraphy. Its use has been limited by reimbursement variability, competition from disease-specific PET agents, and the growth of prostate-specific membrane antigen, or PSMA, PET imaging.
How large is the sodium fluoride F-18 market?
No authoritative public source reports a global, product-specific revenue figure for sodium fluoride F-18. Manufacturers sell it through radiopharmacy networks, and public companies usually combine its revenue with other PET tracers, radiopharmaceuticals, imaging services, or nuclear-medicine products.
The addressable market is best understood as a procedure market rather than a branded-drug market.
Market drivers
- Expansion of PET infrastructure. More PET/CT scanners and radiopharmacies increase the number of facilities capable of using NaF F-18.
- Growth in cancer imaging. Bone metastasis assessment remains clinically relevant across prostate, breast, lung, and other cancers.
- Short production-to-administration cycle. The product is manufactured near the point of care, creating recurring local demand.
- Established regulatory pathway. FDA approval reduces the clinical and procurement risk associated with an established diagnostic agent.
- Potential substitution for conventional bone scans. NaF PET can offer faster imaging and higher diagnostic performance in selected settings.
Market constraints
- Short physical half-life. F-18 has a half-life of approximately 109.7 minutes, requiring regional manufacturing or rapid distribution [2].
- Limited product differentiation. Sodium fluoride F-18 is chemically simple and generally interchangeable when quality, dose, timing, and regulatory compliance are equivalent.
- Reimbursement pressure. Payment is tied to the imaging procedure and payer policy, not only to the injected product.
- Competing PET agents. FDG, PSMA agents, fluciclovine, and other oncology tracers compete for scanner time and clinical preference.
- Protocol-specific use. NaF PET is not the default imaging test for every bone lesion or every cancer indication.
What is the financial trajectory for sodium fluoride F-18?
The expected financial trajectory is mature, stable, and procedure-volume dependent rather than high-growth.
| Financial factor |
Expected effect |
| Unit pricing |
Limited pricing power because the active ingredient is established and competition is possible |
| Volume |
Dependent on PET utilization, oncology referrals, and local protocol adoption |
| Gross margin |
Supported by simple chemistry but pressured by isotope production, delivery, and waste |
| Revenue visibility |
Low at the individual-product level |
| Capital intensity |
High at the network level because cyclotrons, hot cells, quality systems, and delivery infrastructure are required |
| Patent contribution |
Minimal for the core product |
| Market growth |
Likely tied to PET procedure growth rather than NaF-specific innovation |
Revenue model
A sodium fluoride F-18 supplier earns revenue through one or more of four channels:
- Per-dose radiopharmaceutical sales
- Radiopharmacy distribution contracts
- Hospital and imaging-center supply agreements
- Integrated nuclear-medicine services, including production, quality control, delivery, and regulatory support
The short half-life creates a geographic pricing structure. A supplier with a nearby cyclotron and dense delivery routes can achieve better utilization and lower logistics costs than a distant producer. Revenue density is therefore highest in metropolitan areas with multiple PET centers.
Product-level revenue is unlikely to be disclosed by Siemens Healthineers’ PETNET business, Cardinal Health’s nuclear and precision-health operations, Jubilant Radiopharma, Curium, or independent hospital radiopharmacies. Public financial analysis should use segment-level revenue, PET procedure growth, installed scanner capacity, and radiopharmacy footprint as proxies.
How does the short half-life affect market economics?
F-18’s 109.7-minute half-life is the central commercial constraint. The isotope loses activity continuously, reducing the deliverable dose during production, quality release, transport, and administration.
The commercial chain generally follows this sequence:
- Cyclotron production of F-18.
- Synthesis of sodium fluoride F-18.
- Quality-control testing and batch release.
- Dose dispensing.
- Delivery to the imaging site.
- Patient administration within the approved activity window.
The product has no conventional inventory model. Unsold or delayed doses decay and become unusable. Forecasting accuracy, delivery route density, scanner scheduling, and patient appointment adherence directly affect profitability.
Manufacturing and supply-chain barriers
The main barriers are operational rather than chemical:
- Access to an F-18-capable cyclotron
- Radiopharmaceutical manufacturing authorization
- Good manufacturing practice compliance
- Validated synthesis and dispensing systems
- Radiation safety infrastructure
- Qualified personnel
- Short-cycle quality control
- Reliable same-day transportation
- Backup production capacity
These barriers favor established radiopharmacy networks and hospitals with integrated nuclear-medicine operations. They do not create the same long-term monopoly economics associated with a complex biologic or patented small-molecule therapy.
What patents protect sodium fluoride F-18?
The core sodium fluoride F-18 compound has little apparent patent-based protection. Sodium fluoride is an old chemical entity, and F-18 is a radioactive isotope used in diagnostic imaging. The commercial product is generally protected by manufacturing compliance, supply logistics, trademarks, contracts, and facility capabilities rather than by composition-of-matter patents.
| Protection category |
Status for sodium fluoride F-18 |
| Composition-of-matter patent |
No meaningful current barrier expected for the mature sodium fluoride compound |
| Active-ingredient exclusivity |
Expired or commercially immaterial |
| Formulation patent |
Limited relevance because the product is a simple sterile injectable solution |
| Method-of-use patent |
Possible for particular imaging protocols, but not generally central to NaF F-18 sales |
| Manufacturing patent |
Potentially relevant to proprietary equipment or process optimization, not usually to routine NaF production |
| Trademark protection |
Possible at the supplier or product level |
| Trade secrets |
May cover production operations, quality systems, routing, or dose management |
Public FDA labeling identifies sodium fluoride F-18 injection as an approved diagnostic radiopharmaceutical, but the commercial market does not depend on an active product patent [1]. Patent searches should distinguish NaF F-18 from unrelated patents covering PET imaging systems, radiolabeling technologies, automated synthesizers, and other fluorine-18 tracers.
What is the Orange Book status of sodium fluoride F-18?
The FDA Orange Book is relevant for approved drug applications and listed patent or exclusivity information. Sodium fluoride F-18 does not have a commercially significant remaining exclusivity position comparable to a recently approved therapeutic product.
The practical Orange Book assessment is:
- No meaningful remaining new chemical entity exclusivity.
- No durable market barrier based on the sodium fluoride active ingredient.
- No expected pediatric exclusivity advantage.
- No central patent dispute controlling generic or alternative supply.
- Competition determined primarily by manufacturing authorization, distribution, quality, and payer access.
Radiopharmaceutical suppliers may market products under approved applications, outsourcing-facility frameworks, or pharmacy-compounding models, depending on the manufacturing and distribution structure. Those regulatory pathways should not be treated as interchangeable.
When did sodium fluoride F-18 lose exclusivity?
The underlying active ingredient has been available for decades, and sodium fluoride F-18 entered the modern FDA-approved PET market in 2011 [1]. Any FDA exclusivity associated with the original approval has expired. Sodium fluoride F-18 therefore operates as a mature diagnostic product.
The absence of meaningful exclusivity changes the investment thesis. A company cannot reasonably rely on patent term to support premium pricing. Commercial value comes from:
- Production reliability
- Regional delivery coverage
- Hospital contracts
- PET-center relationships
- Radiopharmacy scale
- Regulatory compliance
- Dose scheduling and waste control
Are there Paragraph IV challenges for sodium fluoride F-18?
Paragraph IV litigation is not a material feature of the sodium fluoride F-18 market. Paragraph IV disputes normally arise when a generic applicant challenges listed patents associated with an approved drug application. Sodium fluoride F-18 lacks the type of active patent estate that would ordinarily support a high-value Paragraph IV campaign.
The more likely competitive events are:
- New approved suppliers entering a local market
- Hospital pharmacies shifting from external supply to internal production
- Radiopharmacy contract rebids
- Changes in payer reimbursement
- Substitution by alternative PET tracers
- Competition for cyclotron capacity and delivery routes
No major publicly established Paragraph IV settlement or launch-blocking patent agreement is central to the commercial outlook of sodium fluoride F-18.
What FDA regulatory status applies to sodium fluoride F-18?
FDA approved sodium fluoride F-18 injection in 2011 for PET imaging of bone to define areas of altered osteogenic activity [1]. The product is a diagnostic radiopharmaceutical, not a therapeutic drug.
Regulatory obligations include:
- Drug product approval or an applicable lawful compounding pathway
- Sterility assurance
- Identity, strength, quality, and radiochemical purity testing
- Radiation safety
- Validated production and dispensing
- Time-sensitive release procedures
- Compliance with applicable current good manufacturing practice requirements
The FDA’s radiopharmaceutical framework recognizes that radioactive products require specialized handling, short dating, and release controls. The regulatory burden remains high despite the simple molecular structure.
How does sodium fluoride F-18 compare with competing imaging agents?
| Agent |
Primary imaging role |
Main advantage |
Main limitation |
| Sodium fluoride F-18 |
Bone PET |
High skeletal uptake and high-resolution PET |
Limited disease specificity and short distribution window |
| Technetium-99m bone agents |
Conventional bone scintigraphy and SPECT |
Broad availability and established reimbursement |
Lower resolution and slower workflow |
| F-18 FDG |
Metabolic PET imaging |
Broad oncology use |
May be less specific for osteoblastic bone activity |
| F-18 fluciclovine |
Selected prostate-cancer imaging |
Established use in certain recurrence settings |
Narrower clinical role |
| PSMA PET agents |
Prostate-cancer staging and recurrence |
Disease-specific molecular targeting |
Concentrated in prostate cancer and subject to agent-specific supply |
| F-18 sodium fluoride alternatives under development |
Bone imaging |
Potential protocol or distribution advantages |
Limited commercial differentiation |
NaF PET is strongest when the clinical question concerns osteoblastic activity and the facility has reliable PET access. PSMA PET is more attractive for many prostate-cancer indications because it provides molecular information beyond skeletal turnover. FDG remains the dominant general oncology PET tracer in many institutions.
What patent litigation affects sodium fluoride F-18?
No major product-specific patent litigation is known to control market access for sodium fluoride F-18. Litigation risk is more likely to arise indirectly through:
- Radiopharmacy licensing disputes
- Manufacturing technology claims
- Cyclotron or automated synthesis equipment patents
- Contract disputes involving hospital supply
- Regulatory challenges involving compounding or outsourcing
- Reimbursement litigation affecting PET procedures
This is a lower litigation-risk market than patented oncology therapeutics, where composition, formulation, dosing, and method-of-use patents can create launch-blocking exposure.
What generic launch risks exist?
Generic launch risk is best characterized as supplier-entry risk rather than traditional generic-substitution risk.
A new supplier can pressure pricing if it has:
- Local or regional cyclotron capacity
- A compliant radiopharmaceutical production system
- Access to PET-center customers
- Reliable same-day delivery
- Sufficient patient volume to limit dose waste
- Payer and hospital contracting capability
The principal incumbent risks are contract loss, reduced scanner utilization, and substitution by alternative imaging agents. A distant entrant without a dense distribution network is unlikely to compete effectively despite the absence of patent barriers.
Which companies compete in the sodium fluoride F-18 market?
The competitive landscape includes national radiopharmacy operators, hospital-based nuclear pharmacies, independent PET suppliers, and integrated imaging providers. Relevant market participants may include:
- PETNET Solutions, associated with Siemens Healthineers
- Cardinal Health’s nuclear and precision-health operations
- Jubilant Radiopharma
- Curium
- Independent regional radiopharmacies
- Hospital and academic medical-center cyclotron programs
Participation varies by country and region. A supplier may be a manufacturer in one market, a distributor in another, and a contracted radiopharmacy provider elsewhere.
The most important competitive metric is not global production capacity. It is the number of PET facilities that can be served within the product’s effective delivery window.
What geographic coverage matters most?
North America has a mature PET infrastructure and established radiopharmacy networks. Europe has significant PET capacity but operates through country-specific reimbursement and regulatory frameworks. Asia-Pacific growth is tied to scanner deployment, oncology diagnosis, local isotope production, and regulatory development.
Geographic economics depend on:
- Cyclotron location
- Road and air transport reliability
- Population density
- PET scanner concentration
- National reimbursement
- Hospital procurement structures
- Local radiopharmaceutical regulations
A local producer can have a durable commercial advantage without holding a patent because decay limits the practical service radius.
What is the investment outlook for sodium fluoride F-18?
Sodium fluoride F-18 is unlikely to be an attractive standalone growth asset. Its investment relevance is greater as part of a broader radiopharmacy or PET platform.
Positive factors
- Established FDA-approved diagnostic use
- Recurring demand linked to PET procedures
- Simple chemistry
- High barriers to compliant local manufacturing
- Potential growth in PET capacity
- Low risk of patent expiry-driven revenue collapse
Negative factors
- Limited pricing power
- No meaningful product exclusivity
- Short half-life and dose wastage
- Competition from PSMA and other targeted PET agents
- Reimbursement sensitivity
- Low public revenue disclosure
- Dependence on local logistics and scanner scheduling
The likely financial path is stable-to-modest growth when included in a diversified radiopharmaceutical portfolio. Standalone growth is constrained by substitution and the absence of major clinical differentiation.
Key Takeaways
- Sodium fluoride F-18 is a mature PET diagnostic agent approved by the FDA in 2011.
- Its commercial market is driven by procedure volume, PET capacity, reimbursement, and local radiopharmacy logistics.
- F-18’s 109.7-minute half-life makes manufacturing location and delivery density central to profitability.
- The product has no commercially meaningful remaining exclusivity or patent barrier.
- Paragraph IV litigation and settlement risk are limited.
- Public product-level revenue data are generally unavailable.
- PSMA PET and other targeted agents are the principal competitive threats in oncology imaging.
- The strongest business model is an integrated radiopharmacy platform, not a standalone NaF F-18 product.
- Financial performance is likely to be stable or modestly expanding with PET utilization, but pricing power remains limited.
FAQs
Is sodium fluoride F-18 a generic drug?
It is a mature diagnostic radiopharmaceutical supplied by multiple authorized producers. The market functions like a competitive multisupplier market, although radiopharmaceutical manufacturing and delivery requirements make substitution more operationally complex than ordinary tablet generics.
What is the HCPCS code for sodium fluoride F-18?
Sodium fluoride F-18 is generally billed under HCPCS code A9580, subject to payer rules, coding updates, and applicable Medicare or commercial reimbursement policies [3].
Can hospitals manufacture sodium fluoride F-18 themselves?
Hospitals with appropriate cyclotron capacity, radiopharmaceutical manufacturing systems, qualified personnel, and regulatory authorization may produce sodium fluoride F-18 for internal use. The economics depend on patient volume, equipment utilization, quality-control requirements, and local law.
Is sodium fluoride F-18 better than a technetium bone scan?
NaF PET generally provides higher-resolution and faster skeletal imaging, but technetium bone scanning remains widely available and may be less expensive or more accessible. Clinical choice depends on the indication, equipment, payer policy, and institutional protocol.
Does sodium fluoride F-18 have biosimilar risk?
No. Biosimilar regulation applies to biological products. Sodium fluoride F-18 is a small-molecule radioactive diagnostic agent, so its competitive risk comes from other radiopharmaceutical suppliers and alternative imaging tracers rather than biosimilars.
References
- U.S. Food and Drug Administration. (2011). Sodium fluoride F 18 injection prescribing information. FDA.
- National Institute of Standards and Technology. (2023). Nuclide half-life and decay data: Fluorine-18. NIST.
- Centers for Medicare & Medicaid Services. (2024). HCPCS code A9580: Sodium fluoride F-18, diagnostic, per study dose. CMS.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
- Society of Nuclear Medicine and Molecular Imaging. (2023). Procedure standard for sodium fluoride PET imaging. SNMMI.
